AAPL346.04+2.05 (+0.60%) ▲|ABBV284.56-0.24 (-0.09%) ▼|ABT102.44+1.93 (+1.92%) ▲|ACN251.79+11.53 (+4.80%) ▲|ADBE269.35+14.29 (+5.60%) ▲|AMAT379.67-29.27 (-7.16%) ▼|AMD510.23-42.50 (-7.69%) ▼|AMGN448.43+10.09 (+2.30%) ▲|AMT180.83+3.19 (+1.80%) ▲|AMZN250.25-12.13 (-4.62%) ▼|AVGO324.69-13.11 (-3.88%) ▼|AXP324.15+0.54 (+0.17%) ▲|BA188.42-3.86 (-2.01%) ▼|BAC50.92+0.14 (+0.28%) ▲|BKNG161.73+3.35 (+2.12%) ▲|BLK1,140.28-9.32 (-0.81%) ▼|BMY63.40+2.28 (+3.73%) ▲|BNY144.39-1.47 (-1.00%) ▼|BRK-B549.50+10.51 (+1.95%) ▲|C122.00-1.85 (-1.49%) ▼|CAT700.46-39.75 (-5.37%) ▼|CL97.26+3.86 (+4.13%) ▲|CMCSA22.72+0.64 (+2.91%) ▲|COF203.62-3.05 (-1.47%) ▼|COP146.03+0.36 (+0.25%) ▲|COST1,013.81+15.50 (+1.55%) ▲|CRM249.84+8.06 (+3.33%) ▲|CSCO104.94-2.33 (-2.17%) ▼|CVS94.12+1.34 (+1.44%) ▲|CVX226.22-0.57 (-0.25%) ▼|DE639.41+2.87 (+0.45%) ▲|DHR229.92-3.94 (-1.69%) ▼|DIS112.61+0.78 (+0.70%) ▲|DUK124.83+4.16 (+3.45%) ▲|EMR158.07-5.04 (-3.09%) ▼|FDX302.92+4.69 (+1.57%) ▲|GD348.39+3.68 (+1.07%) ▲|GE290.18-5.70 (-1.93%) ▼|GEV822.47-103.45 (-11.17%) ▼|GILD156.80+3.23 (+2.10%) ▲|GM76.72+0.61 (+0.79%) ▲|GOOG320.83-10.12 (-3.06%) ▼|GOOGL324.44-10.33 (-3.08%) ▼|GS887.73-16.99 (-1.88%) ▼|HD325.72+11.58 (+3.69%) ▲|HON215.32+0.59 (+0.27%) ▲|IBM249.87-1.59 (-0.63%) ▼|INTC86.11-6.85 (-7.37%) ▼|INTU353.97+18.36 (+5.47%) ▲|ISRG441.26+13.14 (+3.07%) ▲|JNJ268.91+11.13 (+4.32%) ▲|JPM334.80-0.39 (-0.12%) ▼|KO94.84+2.16 (+2.33%) ▲|LIN509.77+9.20 (+1.84%) ▲|LLY1,311.52+40.77 (+3.21%) ▲|LMT585.45+33.94 (+6.15%) ▲|LOW203.10+6.54 (+3.33%) ▲|LRCX231.69-29.12 (-11.17%) ▼|MA631.79+9.17 (+1.47%) ▲|MCD251.63+5.38 (+2.18%) ▲|MDLZ64.91+2.17 (+3.45%) ▲|MDT95.58+2.55 (+2.74%) ▲|META645.44-52.08 (-7.47%) ▼|MMM174.08-0.66 (-0.38%) ▼|MO75.86+2.03 (+2.74%) ▲|MRK147.96-1.92 (-1.28%) ▼|MS183.29-3.73 (-1.99%) ▼|MSFT523.97-8.98 (-1.69%) ▼|MU860.14-53.53 (-5.86%) ▼|NEE81.39+3.11 (+3.97%) ▲|NFLX67.22+2.18 (+3.35%) ▲|NKE38.27+0.74 (+1.96%) ▲|NOW156.69+3.57 (+2.33%) ▲|NVDA212.50-9.47 (-4.27%) ▼|ORCL123.41-5.72 (-4.43%) ▼|PEP138.27+3.57 (+2.65%) ▲|PFE30.25+0.40 (+1.34%) ▲|PG166.12+9.28 (+5.92%) ▲|PLTR197.07-4.65 (-2.31%) ▼|PM200.87+3.41 (+1.73%) ▲|QCOM172.75-5.22 (-2.93%) ▼|RTX192.53+0.93 (+0.49%) ▲|SBUX101.62+2.54 (+2.56%) ▲|SCHW92.21+0.57 (+0.62%) ▲|SO93.28+2.89 (+3.20%) ▲|SPG211.18+5.63 (+2.74%) ▲|T22.68+0.77 (+3.49%) ▲|TMO676.83-17.19 (-2.48%) ▼|TMUS158.27+4.52 (+2.94%) ▲|TSLA377.95-8.53 (-2.21%) ▼|TXN283.23-1.42 (-0.50%) ▼|UBER68.21+0.59 (+0.87%) ▲|UNH424.60+7.60 (+1.82%) ▲|UNP296.04+8.17 (+2.84%) ▲|UPS101.69+2.12 (+2.12%) ▲|USB59.91+0.86 (+1.45%) ▲|V413.95+6.10 (+1.50%) ▲|VZ44.80+1.24 (+2.84%) ▲|WFC83.02+0.60 (+0.73%) ▲|WMT120.45+2.65 (+2.25%) ▲|XOM177.34-0.75 (-0.42%) ▼|AAPL346.04+2.05 (+0.60%) ▲|ABBV284.56-0.24 (-0.09%) ▼|ABT102.44+1.93 (+1.92%) ▲|ACN251.79+11.53 (+4.80%) ▲|ADBE269.35+14.29 (+5.60%) ▲|AMAT379.67-29.27 (-7.16%) ▼|AMD510.23-42.50 (-7.69%) ▼|AMGN448.43+10.09 (+2.30%) ▲|AMT180.83+3.19 (+1.80%) ▲|AMZN250.25-12.13 (-4.62%) ▼|AVGO324.69-13.11 (-3.88%) ▼|AXP324.15+0.54 (+0.17%) ▲|BA188.42-3.86 (-2.01%) ▼|BAC50.92+0.14 (+0.28%) ▲|BKNG161.73+3.35 (+2.12%) ▲|BLK1,140.28-9.32 (-0.81%) ▼|BMY63.40+2.28 (+3.73%) ▲|BNY144.39-1.47 (-1.00%) ▼|BRK-B549.50+10.51 (+1.95%) ▲|C122.00-1.85 (-1.49%) ▼|CAT700.46-39.75 (-5.37%) ▼|CL97.26+3.86 (+4.13%) ▲|CMCSA22.72+0.64 (+2.91%) ▲|COF203.62-3.05 (-1.47%) ▼|COP146.03+0.36 (+0.25%) ▲|COST1,013.81+15.50 (+1.55%) ▲|CRM249.84+8.06 (+3.33%) ▲|CSCO104.94-2.33 (-2.17%) ▼|CVS94.12+1.34 (+1.44%) ▲|CVX226.22-0.57 (-0.25%) ▼|DE639.41+2.87 (+0.45%) ▲|DHR229.92-3.94 (-1.69%) ▼|DIS112.61+0.78 (+0.70%) ▲|DUK124.83+4.16 (+3.45%) ▲|EMR158.07-5.04 (-3.09%) ▼|FDX302.92+4.69 (+1.57%) ▲|GD348.39+3.68 (+1.07%) ▲|GE290.18-5.70 (-1.93%) ▼|GEV822.47-103.45 (-11.17%) ▼|GILD156.80+3.23 (+2.10%) ▲|GM76.72+0.61 (+0.79%) ▲|GOOG320.83-10.12 (-3.06%) ▼|GOOGL324.44-10.33 (-3.08%) ▼|GS887.73-16.99 (-1.88%) ▼|HD325.72+11.58 (+3.69%) ▲|HON215.32+0.59 (+0.27%) ▲|IBM249.87-1.59 (-0.63%) ▼|INTC86.11-6.85 (-7.37%) ▼|INTU353.97+18.36 (+5.47%) ▲|ISRG441.26+13.14 (+3.07%) ▲|JNJ268.91+11.13 (+4.32%) ▲|JPM334.80-0.39 (-0.12%) ▼|KO94.84+2.16 (+2.33%) ▲|LIN509.77+9.20 (+1.84%) ▲|LLY1,311.52+40.77 (+3.21%) ▲|LMT585.45+33.94 (+6.15%) ▲|LOW203.10+6.54 (+3.33%) ▲|LRCX231.69-29.12 (-11.17%) ▼|MA631.79+9.17 (+1.47%) ▲|MCD251.63+5.38 (+2.18%) ▲|MDLZ64.91+2.17 (+3.45%) ▲|MDT95.58+2.55 (+2.74%) ▲|META645.44-52.08 (-7.47%) ▼|MMM174.08-0.66 (-0.38%) ▼|MO75.86+2.03 (+2.74%) ▲|MRK147.96-1.92 (-1.28%) ▼|MS183.29-3.73 (-1.99%) ▼|MSFT523.97-8.98 (-1.69%) ▼|MU860.14-53.53 (-5.86%) ▼|NEE81.39+3.11 (+3.97%) ▲|NFLX67.22+2.18 (+3.35%) ▲|NKE38.27+0.74 (+1.96%) ▲|NOW156.69+3.57 (+2.33%) ▲|NVDA212.50-9.47 (-4.27%) ▼|ORCL123.41-5.72 (-4.43%) ▼|PEP138.27+3.57 (+2.65%) ▲|PFE30.25+0.40 (+1.34%) ▲|PG166.12+9.28 (+5.92%) ▲|PLTR197.07-4.65 (-2.31%) ▼|PM200.87+3.41 (+1.73%) ▲|QCOM172.75-5.22 (-2.93%) ▼|RTX192.53+0.93 (+0.49%) ▲|SBUX101.62+2.54 (+2.56%) ▲|SCHW92.21+0.57 (+0.62%) ▲|SO93.28+2.89 (+3.20%) ▲|SPG211.18+5.63 (+2.74%) ▲|T22.68+0.77 (+3.49%) ▲|TMO676.83-17.19 (-2.48%) ▼|TMUS158.27+4.52 (+2.94%) ▲|TSLA377.95-8.53 (-2.21%) ▼|TXN283.23-1.42 (-0.50%) ▼|UBER68.21+0.59 (+0.87%) ▲|UNH424.60+7.60 (+1.82%) ▲|UNP296.04+8.17 (+2.84%) ▲|UPS101.69+2.12 (+2.12%) ▲|USB59.91+0.86 (+1.45%) ▲|V413.95+6.10 (+1.50%) ▲|VZ44.80+1.24 (+2.84%) ▲|WFC83.02+0.60 (+0.73%) ▲|WMT120.45+2.65 (+2.25%) ▲|XOM177.34-0.75 (-0.42%) ▼|
16.1 C
New York
Thursday, October 22, 2026

Tag: diseases

newsFORsourcecompanycontentinformation1releasesmarket

Information on the total number of voting rights and shares

Press Release - Regulated Information 
Press Release - Regulated Information

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb

New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.

20 Years of Lyme Disease Advocacy Fuels New Chapter for Tick BYTES

Founders Offer Do It Yourself Tick Control Tools and Resources WINDHAM, Maine, July 30, 2025 /PRNewswire/ -- Barb and Bob Maurais have launched Tick BYTES (Back Yard...

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.

LXP Industrial Trust Reports Second Quarter 2025 Results

WEST PALM BEACH, FL, July 30, 2025 (GLOBE NEWSWIRE) -- LXP Industrial Trust (“LXP”) (NYSE:LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today announced results for the quarter ended June 30, 2025.

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about July 31, 2025, subject to the satisfaction of customary closing conditions.

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial...

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

GraniteShares Announces Reverse Split of CONI

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute a reverse share split for the GraniteShares 2x Short COIN (the “Fund”). The total market value of the shares outstanding will not be affected as a result of the reverse split.

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

SAN DIEGO, July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers